FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
The key to fibrinolysis and thrombolysis
1502PDF: 263HTML: 125 -
CO36 | Inhibitor titer at diagnosis and clinical course in acquired hemophilia A: a single-center experience C. Simion, B. Stocco, E. Dalla Porta, E. Campello, G. Furlan, L. Spiezia, G. Saggiorato, F. Sartorello, E. Zanon, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
420PDF: 0 -
PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
477PDF: 0 -
PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
493PDF: 0 -
CO34 | Evaluation of emicizumab concentration and thrombin generation in a cohort of severe hemophilia A patients with and without inhibitor A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
505PDF: 0 -
PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy
488PDF: 0 -
Anticoagulation in obese patients: challenges and strategies
1834PDF: 264HTML: 196XML: 78 -
PO67 | Pancreatic cancer in a 71-year-old severe hemophilia A patient with inhibitors and sustained zero bleeding during emicizumab prophylaxis M. Biglietto, A.L. Faccini, S. Sorella, E. Crisanti, M. Antonacci, A. Taglietti, M. Gherardini, A. Tirnetta, S. Ligia, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
509PDF: 0 -
PO78 | Acquired hemophilia A as a paraneoplastic syndrome: two cases report on a rare coexistence M. Gagliardi, L. Capone, A. Ciampa | Centro Emostasi, AORN Moscati, Avellino, Italy
477PDF: 0 -
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1026PDF: 134HTML: 37Appendix: 64 -
PO14 | Searching for safer rescue immunosuppressive therapy protocols in acquired hemophilia A: two case reports G. Quintavalle1, I.M. Tassoni1, B.M. Roccon1, G. Lucchini2, F. Magalini2, M. Zardo2, R. Rossi3, C. Cattabiani3, A. Tagliaferri1, A. Coppola1 | 1SSD Centro HUB Emofilia e MEC; 2UOS Medicina Interna e Reumatologia; 3UO Diagnostica Ematochimica, Azienda Ospedaliero Universitaria, Parma, Italy
421PDF: 0 -
PO90 | Acquired hemophilia A with high-titer inhibitor in a patient with cardiovascular and metabolic comorbidities M.G. Mazzone, G. Chiarelli, R. Russo, L. Valletta Jr, G. D’Errico, C. De Luca, P. Rufolo, A. Tufano, E. Cimino, P. Conca, M.N.D. Di Minno | Department of Clinical Medicine and Surgery, Federico II University of Naples, Italy
521PDF: 0 -
PO77 | The clinical awareness of mixing test interpretation in the era of complex reporting algorithm: do we forget the origins? A. Fassina, L. De Valentin, S. Luzi, R. Turrini, A. Antico, L. Zardo | Laboratorio Analisi Castelfranco Veneto, ULSS Marca Trevigiana, Italy
500PDF: 0 -
PO66 | Viscoelastic tests in disseminated intravascular coagulation associated with aortic aneurysm A. M. Pizzini1, C. Biasoli2, M. Bovara3, E. Gesuete1, A. Fusco1, C. Fantoni1, P. Pedrazzi2, R. Mancini3, M. Silingardi1 | 1Ambulatorio Emostasi & Trombosi, Dipartimento Medico, Ospedale Maggiore AUSL Bologna; 2SSI Presa in Carico delle Malattie Emorragiche e Tromboemboliche della Romagna; 3Laboratorio Unico Metropolitano AUSL Bologna, Italy
511PDF: 0 -
CO33 | Acquired hemophilia A in Liguria, Italy: what six years of data reveal C. Vernarecci1, A. C. Molinari1, P. Ballarino2, M. Caiti2, E. Cenni2, P. Moscatelli2, L. Banov1 | 1IRCCS Istituto Giannina Gaslini, Genova; 2IRCCS Policlinico San Martino, Genova, Italy
453PDF: 0 -
PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven1|9, E. Van Gansewinkel5|10, J. De Bruijne2, F. Eskens3, D. De Groot4, K. Hermans5, N. Mohammad6, F. Van Vilsteren7, C. Verslype8, W. Moris9, M. Roest10, B. De Laat10 , J. De Vos-Geelen5, M. Kramer1|9 | 1Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 2Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; 3Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; 4Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; 5Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 6Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; 7Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; 8Digestive Oncology, University Hospitals Leuven, Belgium; 9Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; 10Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group
60PDF: 12 -
PO65 | Utilization of emicizumab in acquired hemophilia A: a case report C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, G. D’errico, L. Jr Valletta, M. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
469PDF: 0 -
PO55 | Evaluation of safety and efficacy of emicizumab prophylaxis in pediatric patients with hemophilia A – a single centre experience M.L. Tramontano, M. Coppola, S. Coppola, M. Schiavulli | UOSD Centro Regionale Pediatrico Malattie della Coagulazione, Santobono Pausilipon Children Hospital, AORN, Napoli, Italy
427PDF: 0 -
PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis L. Gurgoglione, C.A. Piro, I. Scortechini, I. Battilà, M.C. Merlo, A. R. Scortechini, S. Rupoli, A. Poloni | Hematology Unit, AOU delle Marche-Università Politecnica delle Marche, Italy
399PDF: 0 -
PO67 | TARGETED THERAPIES FOR CANCER AND THE RISK OF ARTERIAL AND VENOUS THROMBOEMBOLISM O. Iqbal | Loyola University Stritch School of Medicine, Maywood, IL, USA
58PDF: 15 -
CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran E. Zanon, C. Simion, A. Napolitano, L. Spiezia, P. Simioni | Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
415PDF: 0 -
PO23 | Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with acquired ADAMTS13 deficiency in emergency settings at the hub laboratory of AUSL Romagna: state of the art and future prospects M. Olivieri1, M. Rosetti1, A. Clementoni1, V. Marinucci1, M. Monterosso1, E. Massari1, V. Polli1, M. Zauli1, V. Sambri2 | 1Clinical Pathology Unit; 2Unit of Microbiology, Area Hub Laboratory, Cesena, Italy
497PDF: 0 -
Crosstalk between hemostasis inhibitors and cholesterol biomarkers in multiple sclerosis
2635PDF: 389Supplementary Files: 112 -
CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients A. Cottonaro1, S. Akula1, B. Pollio2, I. Ricca2, T. Martini2, J. Agnelli Giacchello3, P. Sciancalepore3, R. Santi3, A. Follenzi1,3, S. Merlin1 | 1Università del Piemonte Orientale, Health Sciences, Novara; 2A.O. Città della Salute e della Scienza, SIMT Immunohematology and Transfusion Medicine Service, Diagnostic Department, Torino; 3Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
463PDF: 0 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
492PDF: 0 -
PO20 | DYSFUNCTION OF THE ADAMTS-13/VON WILLEBRAND FACTOR AXIS, MEDIATED BY NETOSIS, AS A DRIVER OF PROTHROMBOTIC STATE AND UNFAVORABLE PROGNOSIS IN ONCOGYNECOLOGICAL PATIENTS V. Bitsadze1, E. Beloborodova2, J. Khizroeva1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Tatarintseva1, J. Christophe Gris1|3, I. Elalamy1|4|5, G. Gerotziafas1|4|5, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Clinic MEDSI Network of Medical Centers in Moscow, Russia; 3Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 4Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 5Hospital Tenon, Paris, France
62PDF: 17 -
PO10 | Clinical and laboratory features of long-Covid syndrome: a cross-sectional study of 1,337 Covid-19 survivors C. Ambaglio1, S. V. Benatti2, C. J. Tartari1,3, L. Russo1,3, S. Bolognini1,3, C. Ticozzi1, F. Schieppati1, V. Brusegan1, S. Venturelli2, L. Barcella1, M. Rizzi2, M. Marchetti1,3, A. Falanga1,3 | 1Department of Immunohematology and Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo; 2Division of Infectious Diseases, Papa Giovanni XXIII Hospital, Bergamo; 3Department of Medicine and Surgery, University of Milan Bicocca, Monza, Italy
493PDF: 0 -
PO91 | Disseminated intravascular coagulation with deep vein thrombosis in a frail patient: an extreme manifestation triggered by sepsis during SGLT2i therapy M. Vacca1, M.V. Cherchi1, S. Che1, G.A.M.L. Costanzo2, D. Firinu2, M. Mantega1, S. Del Giacco2 | 1Ospedale Sirai, ASL Sulcis, 2Università degli Studi di Cagliari, Italy
643PDF: 0 -
PO38 | Rates of hemorrhagic events and hemodialysis circuit thrombosis in patients with end-stage renal disease on hemodialytic treatment receiving a factor-XI inhibitor: a systematic review and meta-analysis D. Santagata, G. Barbui, M.P. Donadini, A. Squizzato | Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese and Como, Italy
464PDF: 0 -
PO57 | Direct oral anticoagulant determination in urine samples compared to plasma concentrations in outpatients with atrial fibrillation and obesity A. Pannunzio1, I.M. Palumbo1, D. Menichelli1, V. Cammisotto2, V. Castellani3, E. Baldacci4, R. Mormile4, A. Chistolini4, G. Bernardini5, N. Porcu1, D. Pastori2, J. Harenberg6, F. Violi2, P. Pignatelli2 | 1Department of General Surgery, Surgical Specialties and Organ Transplantation Paride Stefanini, Sapienza University of Roma, Italy; 2Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy; 3Department of Translational and Precision Medicine, Sapienza University of Roma, Italy; 4Department of Hematology, Oncology and Dermatology, Sapienza University of Roma, Italy; 5U.O.S.D. Medicina Rigenerativa DAI, Medicina Diagnostica e Radiologia, Policlinico Umberto 1, Roma, Italy; 6Ruprecht Karls University of Heidelberg, Germany
408PDF: 0 -
PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
612PDF: 0 -
PO30 | Acquired angioedema associated with B-non Hodgkin lymphoma: a case report A. Pozzi, G. Rosati, S. Pizzimenti, M. Padrini, S. Laurenti, G. Ferrari, R. M. Medici, C. Barale, I. Russo, A. Morotti | Univeristy of Turin, AUO San Luigi Gonzaga, Orbassano (TO), Italy
421PDF: 0 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
428PDF: 60HTML: 44Supplementary: 20Appendix: 34
1 - 40 of 40 items
